Anti-Glial/Neuronal Nuclear Antibody-Type 1 (AGNA-1) Titer, Serum
Use
This test is useful for reporting an end titer result from serum specimens and for the serological evaluation of patients with subacute neurological disorders of undetermined etiology, especially those with risk factors for primary lung carcinoma. It aids in directing a focused search for cancer and in investigating neurological symptoms arising during or after cancer therapy that cannot be explained by metastasis. Additionally, it helps differentiate autoimmune neuropathies from neurotoxic effects of chemotherapy and assists in monitoring the immune response of seropositive patients during cancer therapy. The test can detect early evidence of cancer recurrence in previously seropositive patients.
Special Instructions
Not provided.
Limitations
AGNA-1 is challenging to detect by immunofluorescence when coexisting with other neuronal nuclear autoantibodies unless its titer exceeds that of the others. The autoantibody has not been detected by Western blot, and interference by non-neuron-specific autoantibodies can usually be mitigated by serologic absorption.
New York Approved
Methodology
Immunoassay (Indirect Immunofluorescence Assay (IFA))
Biomarkers
AGNA-1
Antibody
LOINC Codes
- 94341-5 - Glial nuc type 1 IgG Titr Ser IF
- 94341-5 - Glial nuc type 1 IgG Titr Ser IF
Result Turnaround Time
6-8 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
Not provided
Minimum Volume
0.6 mL
Collection Instructions
Serum is preferred. Spinal fluid testing is particularly useful if interfering antibodies are present in the serum.
Causes for Rejection
Gross hemolysis, gross lipemia, and gross icterus are causes for rejection.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 28 days |
| Frozen | 28 days |